Press Room - Specialised Therapeutics - Page 2

PHARMA IN FOCUS By Nick Lush 15 March 2021 Is This a Funding Breakthrough? With the Zimmerman inquiry being told the PBAC is not up to scratch on delivering medicines to Australian patients, a ‘thinking outside the square’ option being pioneered by local pharmaSpecialised Therapeutics (STA) appears to be blazing a new funding trail. STA

The following stories appeared on Channel 10 News and other news outlets nationally. Click on the thumbnails below to view them. Breast Surgeon Dr Jane O’Brien on Channel 10 News Breast Cancer Surgeon Dr Chantel Thornton on ABC News   Breast Cancer Surgeon Dr Chantel Thornton on 7 News Breast Surgeon Dr Jane O’Brien on

Watch Video Click on the video banner above to watch CEO Carlo Montagner discuss STA’s 2020 Employer of Choice award on Ticker News. For more information visit https://employerofchoiceawards.com.au/eoc-winners-2020/specialised-therapeutics-2020-eoc/

PHARMADISPATCH 6 November 2020 Australians Will Need to ‘Reconcile Themselves to this New Reality’ November 6, 2020 — Privately owned Australian pharmaceutical company Specialised Therapeutics Asia has signed an exclusive distribution agreement for a new therapy to treat advanced gastrointestinal stromal tumours (GIST). The agreement with US-based Deciphera Pharmaceuticals covers the commercialisation of switch-control tyrosine kinase

PHARMADISPATCH 6 November 2020 Australian Company Adds to its Oncology Portfolio with GIST Therapy     November 6, 2020 — Privately owned Australian pharmaceutical company Specialised Therapeutics Asia has signed an exclusive distribution agreement for a new therapy to treat advanced gastrointestinal stromal tumours (GIST). The agreement with US-based Deciphera Pharmaceuticals covers the commercialisation of switch-control

BIOSPACE 16 July 2020 New Early Breast Cancer Drug Now Approved in Malaysia SINGAPORE, July 16, 2020 /PRNewswire/ — A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have

PHARMA IN FOCUS By Megan Brodie 16 April 2020 PBAC fees too high for little guy The owner of Australia’s largest independent pharmaceutical company says changes to PBAC fees mean small companies need to budget almost $2 million to make a submission for a medicine to be listed on the PBS, with no guarantee of

Pharma Dispatch 16 April 2020 STA: New fees a “major barrier” to patient access Specialised Therapeutics Australia says proposed further increases in PBS submission and listing fees are “prohibitive” for smaller companies and risk becoming a “major barrier” to patient access to new medicines. The Department of Health recently announced new and higher cost recovery

THE COURIER MAIL By Sue Dunlevy 22 February 2020 Breast cancer test fail Government denies funding to help avoid chemo A $5000 test that can indicate whether a breast-cancer patient needs chemotherapy has been rejected for a government subsidy even though it could potentially save thousands of women from having to undergo the harrowing cancer

THE DAILY TELEGRAPH By Sue Dunlevy 22 February 2020 Tussle over cancer test Rejection angers support group A $5000 test that can indicate whether a breast cancer patient needs chemotherapy has been rejected for a government subsidy, even though it would mean thousands of women could avoid the harrowing treatment. The government’s Medical Services Advisory